OLK vs. TXG, CTKB, LAB, QTRX, VREX, LNTH, SEER, BIO.B, BIO, and PTCT
Should you be buying Olink Holding AB (publ) stock or one of its competitors? The main competitors of Olink Holding AB (publ) include 10x Genomics (TXG), Cytek Biosciences (CTKB), Standard BioTools (LAB), Quanterix (QTRX), Varex Imaging (VREX), Lantheus (LNTH), Seer (SEER), Bio-Rad Laboratories (BIO.B), Bio-Rad Laboratories (BIO), and PTC Therapeutics (PTCT). These companies are all part of the "medical" sector.
Olink Holding AB (publ) (NASDAQ:OLK) and 10x Genomics (NASDAQ:TXG) are both mid-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their analyst recommendations, institutional ownership, risk, earnings, community ranking, media sentiment, profitability, valuation and dividends.
In the previous week, 10x Genomics had 10 more articles in the media than Olink Holding AB (publ). MarketBeat recorded 14 mentions for 10x Genomics and 4 mentions for Olink Holding AB (publ). Olink Holding AB (publ)'s average media sentiment score of 1.75 beat 10x Genomics' score of 0.46 indicating that Olink Holding AB (publ) is being referred to more favorably in the media.
Olink Holding AB (publ) presently has a consensus target price of $26.00, indicating a potential upside of 8.74%. 10x Genomics has a consensus target price of $48.50, indicating a potential upside of 114.03%. Given 10x Genomics' stronger consensus rating and higher possible upside, analysts plainly believe 10x Genomics is more favorable than Olink Holding AB (publ).
Olink Holding AB (publ) has a beta of 0.5, suggesting that its share price is 50% less volatile than the S&P 500. Comparatively, 10x Genomics has a beta of 1.94, suggesting that its share price is 94% more volatile than the S&P 500.
30.2% of Olink Holding AB (publ) shares are held by institutional investors. Comparatively, 84.7% of 10x Genomics shares are held by institutional investors. 10.0% of 10x Genomics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
10x Genomics received 29 more outperform votes than Olink Holding AB (publ) when rated by MarketBeat users. Likewise, 52.56% of users gave 10x Genomics an outperform vote while only 34.29% of users gave Olink Holding AB (publ) an outperform vote.
Olink Holding AB (publ) has higher earnings, but lower revenue than 10x Genomics. Olink Holding AB (publ) is trading at a lower price-to-earnings ratio than 10x Genomics, indicating that it is currently the more affordable of the two stocks.
Olink Holding AB (publ) has a net margin of -19.72% compared to 10x Genomics' net margin of -42.20%. Olink Holding AB (publ)'s return on equity of -7.07% beat 10x Genomics' return on equity.
Summary
10x Genomics beats Olink Holding AB (publ) on 11 of the 18 factors compared between the two stocks.
Get Olink Holding AB (publ) News Delivered to You Automatically
Sign up to receive the latest news and ratings for OLK and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding OLK and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Olink Holding AB (publ) Competitors List
Related Companies and Tools
